#tecovirimat

[transparentgentlemenmarker]

Le pneumologue allemand Dr. Wofgang Wodarg annonce : Ce qu'on nous vend comme la variole du singe appelée Monkeypox, actuellement mpox est dans la plupart des cas ce qu'on appelle le zona, l'un des effets secondaires les plus fréquents du vaccin Covid. La variole du 🐵 est commercialisée pour cacher les effets secondaires ❔❔❔

Serait-ce nôtre fin annoncée où un retour aux origines. Les premiers signes peuvent apparaître cela commence par un syndrome grippal une grosse fièvre, des courbatures, des maux de gorge.

Puis des adénopathies, c'est-à-dire des ganglions disséminés, des éruptions cutanées

Il y a deux clades il faut comprendre deux variants du virus qui sont historiquement identifiés. Le clade I est diffusé en Afrique centrale. Le clade II sévit en Afrique de l'Ouest. C'est une maladie virale et d'origine zoonotique. Il existe un antiviral, le tecovirimat

Aux jeunes vous avez la chance de rayer le plus de lignes possible

Préparez-vous à un dépistage de masse

[queerforscience]

"Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other)"

.. and this didn't adjust for HIV status, so given the existing disparities in both HIV prevalence and viral suppression among people living with HIV, Black patients especially in addition to Hispanic and/or Latino/a/x/e patients likely should have received tecovirimat more often than white patients.

[illnessfaker]

thread on mpox (previously known as monkeypox) by a vaccine researcher.

key points:

mpox is not new & it is not like covid

smallpox vaccines are effective against mpox ("at least 86%")

"JYNNEOS (Imvanex, IMVAMUNE) is a non-replicating vaccine for smallpox that CAN BE USED SAFELY in immunocompromised individuals and individuals with skin conditions such as eczema against Mpox"

WHO declared public health emergency status due to surge in cases in & around the DRC (i'm assuming this spread of the disease is linked to the crisis)

"we also have some antiviral drugs (such as Tecovirimat) that can help treat those who are already infected. Vaccinia immune globulin (VIG) can be used against monkeypox"

you should be able to get the jynneos vaccine at your local pharmacy if you are concerned about exposure!

stay safe folks 🫡

[covid-safer-hotties]

Also preserved on our archive (That's right: We do more than just covid!)

By Lisa Schnirring

Genetic sequencing has identified a second cluster of tecovirimat-resistant mpox infections in the United States—the first of its kind involving interstate spread. Researchers from the US Centers for Disease Control and Prevention (CDC) and partners from five affected states reported their findings yesterday in Morbidity and Mortality Weekly Report.

The first Tpoxx-resistant cluster was identified in California in late 2022 and early 2023 in people who hadn't previously been treated with the drug. The new report describes a new unrelated cluster among 18 people with no previous treatment across multiple states.

Sequencing identified a unique combination of resistance mutations in 20 specimens collected from 18 patients between October 2023 and February 2024. The patients were from five states: Illinois (8), California (5), Louisiana (2), Texas (2), and New York (1).

Of 16 patients with an available treatment history, one had received the drug before the sample was collected. Of 17 patients with available clinical data, illnesses were mild and similar to standard clade 2 infections, though two were hospitalized for pain management.

Findings likely underestimate spread of resistant variant In vitro testing of seven samples showed resistance to Tpoxx. Whole-genome sequencing showed that the resistance mutations came from a common ancestor but were distinct from the earlier California cluster.

Researchers said because not all viruses from mpox cases are sequenced, the findings likely underestimate the prevalence of the newly identified drug-resistant variant. They added that more surveillance is needed, as well as adherence to CDC Tpoxx use protocols. Also, they wrote that the findings underscore the need for more treatments for mpox, along with smallpox biothreat preparedness.

Study link: www.cdc.gov/mmwr/volumes/73/wr/mm7340a3.htm?s_cid=mm7340a3_e&ACSTrackingID=USCDC_921-DM138236&ACSTrackingLabel=This%20Week%20in%20MMWR%3A%20Vol.%2073%2C%20October%2010%2C%202024&deliveryName=USCDC_921-DM138236#contribAff

[broadlyepi]

MMWR Booster #6: Clinical and Epidemiologic Characteristics of Mpox Cases from the Initial Phase of the Outbreak — New York City, May 19–July 15, 2022

Top 5 Takeaways:

Demographics and Risk Behaviors: Among 719 mpox patients in NYC, 97.9% were men, predominantly identifying as gay or queer (78.7%), or bisexual (5.6%). A significant proportion reported intimate or sexual contact with men, which appears to have been a key risk factor.

Symptomatology: Prodromal symptoms were noted in 38.1% of cases. Notably, 45.1% reported proctitis or rectal symptoms, with a majority not observing perianal skin lesions. Ophthalmic manifestations were seen in 6.2% of patients.

Diagnostic Delays and Treatment: The median time from symptom onset to diagnosis was 5 days. Tecovirimat was administered to 14.0% of patients, and 4.9% required hospitalization.

Importance of Anorectal Swabs: Over two-thirds of patients with rectal symptoms lacked perianal lesions, suggesting the potential utility of anorectal swabs in diagnosis, despite current protocols focusing on swabbing skin lesions.

Data Completeness and Public Health Implications: Data on gender, race, ethnicity, and sexual orientation were over 80% complete, aiding public health outreach. The study’s findings can inform public health messaging and clinical management strategies.

link: BroadlyEpi.com

[noticiasmundiales787]

🔴La Viruela Símica del Virus mpox: Una Alerta de Emergencia Global a Nivel Mundial

🔴La #viruelasímica (#mpox), declarada Emergencia de Salud Pública de Importancia Internacional por la OMS, es una enfermedad zoonótica causada por el virus de la viruela del mono (MPXV), perteneciente a la familia Poxviridae. La Viruela Símica se caracteriza por síntomas como fiebre, erupciones cutáneas dolorosas que progresan a costras, inflamación de los ganglios linfáticos, dolores musculares y fatiga. Su transmisión ocurre por contacto directo con lesiones cutáneas, fluidos corporales, partículas respiratorias o superficies contaminadas. También puede propagarse de animales a humanos mediante mordeduras, arañazos o manipulación de carne infectada.

🔴En el brote global iniciado en 2022 de la Viruela Símica o #virusmpox, el clado IIb del virus ha afectado principalmente a personas en redes de contacto cercano, incluidas comunidades LGBTQ+. La OMS ha reforzado las medidas de vigilancia epidemiológica, acceso equitativo a vacunas y tratamientos, y campañas contra la estigmatización de las comunidades afectadas.

🔴Aunque no existe un tratamiento específico para el virus mpox, antivirales como el tecovirimat han mostrado eficacia en casos graves. La vacunación preventiva es clave para personas en riesgo, como trabajadores de salud, contactos cercanos y aquellos con múltiples parejas sexuales. Las medidas de prevención incluyen el aislamiento de casos confirmados, uso de mascarillas, higiene constante y evitar el contacto con lesiones o superficies contaminadas.

🔴La enfermedad puede ser más grave en niños, personas embarazadas y aquellas con sistemas inmunitarios debilitados, como quienes viven con VIH no controlado. La OMS insiste en la importancia de acudir al médico ante síntomas y de seguir protocolos para frenar su propagación.

[snehalblog]

Global Mpox Treatment Market: Insights into Diagnostic and Therapeutic Developments - UnivDatos

According to a new report by UnivDatos Market Insights, The Mpox Treatment Market was valued at approximately USD 1,025.46 million in 2023 and is expected to grow at a substantial CAGR of around 10.86% during the forecast period (2024-2032). This is mainly due to several key factors that contribute to its rapid growth. The growing number of zoonotic infections is one of them because the increased contact with animals poses higher threats of diseases such as mpox to affect humans. This has brought awareness and the need for treatment and the prevention of such diseases into the limelight. Another factor is the governmental programs and grants as the promotion of high-risk vaccines and other antiviral therapeutics, including Tecovirimat which has already received the approval of regulatory authorities in some countries. Mpox is identified to be an internationally infectious zoonotic viral disease that has been both transported globally and travelled to different countries as the world continues to globalize and as people travel. Further, the rising patient awareness to advance mpox treatment through public-private partnerships for better research and development of mpox drugs and vaccines is also driving the growth of mpox treatment market.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=68167&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

For instance, in September 2023, BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox. Through this partnership, CEPI will provide funding of up to $90 million to support the development of mRNA-based vaccine candidates.

There has been a recent upsurge in the mpox outbreak in the several areas located in North America and more so in the US which has been receiving the highest ripple effect from the mpox breakout. Upto March 16, 2024 this year, United States has reported 511 cases which is two folds as of United States reported in this similar time span in the year 2023 and had less than 300 cases. There exists greater growth potential in this region following subsequent funding for the development of new antiviral drugs and vaccines. Thus, actions that the authorities have taken with an eye to the extension of the demand for genetic engineering to produce vaccines for mpox can also embrace a positive function in the enhancement of the chance to treat mpox. Moreover, availability of therapeutics in the region also results into growth for this market.

For instance, in April 2024, Bavarian Nordic A/S announced that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.

Increasing Prevalence of mpox is driving high demand in Canada

The current high rate of mpox infection in Canada is very influential in determining the need for treatment and prevention measures. Since outbreak in May 2022, Canada has recorded 1,541 mpox cases as of August 17, 2024, and most of them in Ontario, Quebec, and British Columbia. Additionally, governmental support such as increased support and surveillance is further assisting in mpox treatment market growth. For instance, with growing cases of mpox, Canada’s government states and health agencies of Canada are monitoring the global mpox situation closely and working with domestic and international partners to determine opportunities for support. The Public Health Agency of Canada (PHAC) has recently ensured the administration of Imvamune vaccine which is decisive for the prevention of mpox among the targeted groups. It makes vaccination campaigns a critical requirement, apart from disease outbreaks, due to their importance in reducing the number of severe cases that utilize the health facilities.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=68167&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

Thus, the market in North America has great growth potential, because the region has a high prevalence of mpox. With the availability of advanced technologies including the use of AI for rapid drug discovery and presence of key market players within this region, the mpox treatment market is increasing significantly in the continent. The commitment that North America has made to bring innovation in this market further escalates North America’s position as the leading region for mpox treatment market growth. According to the Univdatos Market Insights analysis, the rise of prevalence of mpox, increasing mpox vaccination, government support, and increasing focus towards preventive measures drive the mpox treatment market. As per their “Mpox Treatment Market” report, the global market was valued at USD 1,025.46 million in 2023, growing at a CAGR of about 10.86% during the forecast period from 2024 - 2032.

[cailynnjohnson]

A New Potential Medication to Fight the Monkey Pox Virus

The monkeypox virus, also called MPOX virus, which is rapidly spreading throughout the world's nations, has posed a significant risk to the health of the people, resulting in many deaths. The news reported that patients with immunodeficiency are at high risk of getting this virus in particular. And the current monkeypox outbreak first occurred outside of Africa and was also transmitted from human to human. As a result, it is critical to create efficient medications or vaccinations to combat this virus and protect individuals from getting sick. In recent years, extensive research regarding the monkeypox virus has been conducted across the world. Meanwhile, there is also good news for the global nation that some surprising findings have been discovered.

Recently, a scientific team from Goethe University and the University of Kent published a study paper in the Journal of Medical Virology. The paper showed that the scientific team had discovered a compound called nitroxoline that might be useful in fighting the disease. According to the research team, Nitroxoline is a promising drug candidate for the monkeypox virus, and it is also effective against a tecovirimat-resistant strain of the monkeypox virus as well as against other viral and bacterial pathogens that are frequently co-transmitted with monkeypox viruses, which means that it simultaneously suppresses multiple pathogens that are frequently involved in severe courses of monkeypox.

This new finding is caused by the great concern of researchers working in this field. At the same time, it also gives people who are suffering from the disease great hope. Although there are no effective drugs developed to treat people who are suffering from the monkeypox virus, new findings will greatly motivate the discovery of new therapies and effective monkeypox vaccines.

In order to help researchers accelerate the discovery of available therapies for the monkeypox virus, multiple monkeypox virus products (only for research use) and innovative solutions are provided by diverse laboratories or life science companies, such as the nucleic acid-based anti-monkeypox drug discovery solutions and inhibitor-based anti-monkeypox drug discovery solutions provided by Creative Biolabs that are flexible according to researchers' demands.

Founded with promises to build a healthier world, Creative Biolabs, a US-based biotech company, has come forward with a comprehensive set of services and solutions to advance the discovery of monkeypox antibodies and new therapies, as well as utilizing cutting-edge technologies and development platforms to support clients' research regarding monkeypox and reduce the international spread of this virus.

[rajco1]

What You Need to Know About Mpox Cases in California

November 17, 2024

Mpox Overview

Definition: Monkeypox virus disease.

Transmission: Skin-to-skin contact, contaminated objects.

Symptoms: Rash, fever, headache and fatigue.

California Mpox Cases

Case Count: 987 confirmed cases (California Department of Public Health).

Regions Affected: Los Angeles, San Francisco, San Diego.

Demographics: Primarily affects men who have sex with men.

Prevention Strategies

Vaccination: JYNNEOS and ACAM2000 vaccines.

Safe Sex Practices: Condoms, gloves.

Hygiene: Frequent handwashing.

Social Distancing: Avoid close contact.

Symptoms and Testing

Early Detection: Monitor for symptoms.

Lab Testing: PCR, serology tests.

Medical Consultation: Immediate evaluation.

Treatment and Care

Antiviral Medication: Tecovirimat.

Supportive Care: Pain management, hydration.

Isolation: Prevent transmission.

[kazifatagar]

Monkey Pox Vaccines to be Distributed for High-Risk Cases

Health Minister Datuk Seri Dzulkefly Ahmad has confirmed that the monkey pox vaccine will be distributed in Malaysia through the Covid-19 ASEAN Response Fund. He said the MVA-BN vaccine and the Antiviral Tecovirimat (TPOXX) medication will be distributed in the country although he did not disclose when, according to a post on his X account. Monkey Pox vaccines to be distributed for high-risk…

[thenetsight]

Promising Mpox Drug Fails in Trials as Virus Spreads

As mpox continues to spread in Central Africa, a promising antiviral drug to treat the infection has failed to improve patients’ symptoms in a trial in the Democratic Republic of the Congo, the epicenter of the outbreak. In the trial, the drug tecovirimat, also known as TPOXX, did not alleviate the characteristic blisterlike rash seen in people with mpox, formerly known as monkeypox. In an…

[centraldenoticiasmx]

Fármaco contra la cepa de viruela del mono no responde como se espera

🖊#Salud | Fármaco contra la cepa de viruela del mono no responde como se espera +INFO:

Recientes investigaciones pusieron en duda la efectividad de un fármaco utilizado para tratar la viruela del mono, una enfermedad que ganó atención global debido a la propagación de cepas peligrosas en diversas regiones de África. El tecovirimat, antiviral desarrollado inicialmente para combatir la viruela, mostró resultados decepcionantes en un ensayo llevado a cabo en la República Democrática…

[scientificinquirer-blog]

DAILY DOSE: Antiviral Drug Fails to Speed Monkeypox Healing; Global Tourism Surge Brings Growth and Environmental Challenges.

TECOVIRIMAT NOT EFFECTIVE FOR CLADES I MPox PATIENTS A recent clinical trial in the Democratic Republic of the Congo (DRC) revealed that the antiviral drug tecovirimat did not significantly accelerate healing for patients with the clade I strain of monkeypox, which is considered more lethal than clade II. Despite its use in treating mpox, tecovirimat’s effectiveness remains uncertain due to…

[iamnaturalnana]

The FDA Approved an Anti-Bioterrorism Drug Meant to Treat Smallpox

The Food and Drug Administration (FDA) on Friday approved the first drug specifically designed to treat smallpox ��� despite the fact that the disease was officially eradicated in 1980. While the daily threat of smallpox, which is caused by the variola virus, is virtually non-existent, FDA Commissioner Scott Gottlieb said in a statement that the drug, called TPOXX, or tecovirimat, could be a…

[insideoutvietnam]

SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced today an agreement to expand access to TPOXX (tecovirimat) to the member states in the Association of Southeast Asian Nations (ASEAN), a political and economic union in the region. This agreement, which was signed by the Ministry…